Harnessing methods, data analysis, and near-real-time wastewater monitoring for enhanced public health response using high throughput sequencing
Not Available
Engineering topics
Publications and source records attributed to Brown, Eric.
Not Available
Explore the source record for details and available documents.
Explore the source record for details and available documents.
ABSTRACT Wastewater surveillance has emerged as a crucial public health tool for population-level pathogen surveillance. Supported by funding from the American Rescue Plan Act of 2021, the FDA‘s genomic epidemiology program, GenomeTrakr, was leveraged to sequence SARS-CoV-2 from wastewater sites across the United States. This initiative required the evaluation, optimization, development, and publication of new methods and analytical tools spanning sample collection through variant analyses. Version-controlled protocols for each step of the process were developed and published on protocols.io. A custom data analysis tool and a publicly accessible dashboard were built to facilitate real-time visualization of the collected data, focusing on the relative abundance of SARS-CoV-2 variants and sub-lineages across different samples and sites throughout the project. From September 2021 through June 2023, a total of 3,389 wastewater samples were collected, with 2,517 undergoing sequencing and submission to NCBI under the umbrella BioProject,PRJNA757291. Sequence data were released with explicit quality control (QC) tags on all sequence records, communicating our confidence in the quality of data. Variant analysis revealed wide circulation of Delta in the fall of 2021 and captured the sweep of Omicron and subsequent diversification of this lineage through the end of the sampling period. This project successfully achieved two important goals for the FDA’s GenomeTrakr program: first, contributing timely genomic data for the SARS-CoV-2 pandemic response, and second, establishing both capacity and best practices for culture-independent, population-level environmental surveillance for other pathogens of interest to the FDA. IMPORTANCE This paper serves two primary objectives. First, it summarizes the genomic and contextual data collected during a Covid-19 pandemic response project, which utilized the FDA’s laboratory network, traditionally employed for sequencing foodborne pathogens, for sequencing SARS-CoV-2 from wastewater samples. Second, it outlines best practices for gathering and organizing population-level next generation sequencing (NGS) data collected for culture-free, surveillance of pathogens sourced from environmental samples.
Explore the source record for details and available documents.
This article is set during the 1944 and 1945 final push to complete Project Y—the Manhattan Project at Los Alamos—and focuses primarily on overcoming the challenge of creating and demonstrating a successful convergent explosive implosion to turn a subcritical quantity of plutonium into a critical mass. The critical mass would then efficiently yield kilotons of trinitrotoluene (TNT)-equivalent energy in about a microsecond, demonstrating the implosion atomic bomb concept. This work culminated in the Trinity atomic test near Alamogordo on July 16, 1945. This implosion effect demarcated the approach to explosive science and technology the Laboratory has followed ever since, including development of high-explosive synthesis and formulation, small and large test and diagnostic facilities, shock dynamics theory, high-explosive system design engineering, and three-dimensional implosion modeling and simulation using some of the fastest computers in the world. This work also ushered in a period of broader application of precision high explosives in conventional munitions, demolition, mining and oil exploration, and space travel.